Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, ...

Unionized workers at fast-growing South Korean CDMO Samsung Biologics kicked off a planned general strike on Friday, ...

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...

Looking to clarify its expectations on manufacturer responses following inspections, the FDA earlier this year unveiled, for ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...

Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...

As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...